Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares gapped down before the market opened on Wednesday . The stock had previously closed at $23.38, but opened at $21.85. Dianthus Therapeutics shares last traded at $23.05, with a volume of 21,600 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on DNTH shares. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Guggenheim restated a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $52.14.

Dianthus Therapeutics Stock Down 5.5 %

The company’s 50-day moving average is $22.65 and its 200-day moving average is $24.97. The stock has a market capitalization of $653.95 million, a price-to-earnings ratio of -8.81 and a beta of 1.82.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the stock. Quest Partners LLC grew its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Dianthus Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after purchasing an additional 7,854 shares during the last quarter. Walleye Capital LLC purchased a new position in shares of Dianthus Therapeutics during the third quarter worth approximately $821,000. Finally, Braidwell LP raised its holdings in shares of Dianthus Therapeutics by 34.6% in the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after buying an additional 126,836 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.